Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors

Simona Verzeletti, Chiara Bonini, Sarah Marktel, Nadia Nobili, Fabio Ciceri, Catia Traversari, Claudio Bordignon

Research output: Contribution to journalArticle

Abstract

We previously demonstrated that severe graft-versus-host disease (GVHD), associated with the therapeutic infusion of donor lymphocytes after allogeneic marrow transplantation (BMT), can be efficiently controlled by the SFCMM-2-mediated expression of the herpes simplex virus thymidine kinase (HSV-tk) suicide gene into the allogeneic lymphocytes. This was achieved by selective elimination of transduced lymphocytes by ganciclovir (GCV) infusion. Despite the positive results of the pilot clinical trial, two vector-related limitations were observed. The induction of a strong immune response against genetically modified cells was observed in two patients. In addition, the only patient who developed chronic GVHD showed only partial response to ganciclovir treatment. In an attempt to overcome these limitations, we developed a new generation of vectors. The neomycin resistance (neo(R)) gene was removed from the SFCMM-3 and SFCMM-4 retroviral vectors. These vectors are less immunogenic and able to confer higher ganciclovir sensitivity to transduced human lymphocytes. All the vectors carry a modified form of the low-affinity nerve growth factor receptor cDNA, as cell surface selectable marker (ΔLNGFR). The vectors were compared in terms of gene transfer efficiency, and ability to confer high and specific sensitivity to ganciclovir. The SFCMM-3 vector, carrying the entire HSV-tk gene driven by the LTR promoter, allows efficient transduction of human T lymphocytes and confers the highest GCV sensitivity to transduced lymphocytes with a high and a low proliferation index. The expression of the ΔLNGFR marker allows an easier in vitro manipulation and a faster immune selection of transduced cells compared with neo(R) selection. Finally, the elimination of the neo(R) gene removes a potent immunogen from transduced lymphocytes.

Original languageEnglish
Pages (from-to)2243-2251
Number of pages9
JournalHuman Gene Therapy
Volume9
Issue number15
Publication statusPublished - Oct 10 1998

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors'. Together they form a unique fingerprint.

  • Cite this